On July 25, Representatives Andy Harris, M.D. (R-MD-01), Earl Blumenauer (D-OR-03), H. Morgan Griffith (R-VA-09), and Zoe Lofgren (D-CA-19) introduced H.R. 3391 (the Medical Marijuana Research Act of 2017).
The Medical Marijuana Research Act of 2017 amends the Controlled Substances Act to make marijuana accessible for use by qualified marijuana researchers for medical purposes, and for other purposes.
Under present law, clinical investigations involving cannabis must meet approval from various federal agencies, including the DEA, the FDA, and the NIDA. Only cannabis provided by the NIDA may be used in clinical trials.
Please contact your members of the US House and Senate and urge their support for these important measures.